- Report
- August 2022
United States
From €1865EUR$1,940USD£1,600GBP
- Report
- August 2022
Global
From €760EUR$790USD£652GBP
- Report
- February 2021
Global
From €2846EUR$2,960USD£2,442GBP
- Report
- September 2021
- 49 Pages
Global
From €3841EUR$3,995USD£3,295GBP
- Clinical Trials
- January 2020
- 498 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- December 2021
- 130 Pages
Global
From €10572EUR$10,995USD£9,069GBP
- Drug Pipelines
- October 2020
- 134 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- February 2024
- 96 Pages
Global
From €3500EUR$3,899USD£3,108GBP
- Report
- July 2022
- 128 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- June 2023
- 132 Pages
Global
From €913EUR$950USD£784GBP
- Report
- February 2023
- 268 Pages
Global
From €5510EUR$5,730USD£4,727GBP
The Overactive Bladder Drug market is a subset of the Urological Disorders Drugs market. It is composed of drugs used to treat overactive bladder, a condition characterized by frequent urination, urgency, and incontinence. These drugs work by relaxing the bladder muscles, reducing the urge to urinate, and improving bladder control. Commonly used drugs include anticholinergics, beta-3 agonists, and muscarinic receptor antagonists. These drugs are available in both oral and topical formulations.
The Overactive Bladder Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Astellas Pharma, Allergan, Merck, Sanofi, and GlaxoSmithKline. Show Less Read more
